Patients who have truncus arteriosus with moderate or worse initial truncal valve regurgitation or stenosis may be at risk for truncal valve intervention.
Coronary cannulation failures following transcatheter aortic valve replacement were found to be higher in patients receiving Evolut TAVs.
Outcomes of transfemoral TAVR for symptomatic severe aortic stenosis were comparable with the self-expanding transcatheter ACURATE neo valve or the CoreValve Evolut valve.
Tricuspid annular dilation may be an independent predictor of all-cause mortality after transcatheter aortic valve replacement for severe aortic stenosis.
Long-term mortality rates were lower in patients undergoing transcatheter aortic valve implantation who were overweight vs obese or normal weight.
The second-generation SAPIEN XT balloon-expandable valve was found to have a higher 5-year rate of structural valve deterioration compared with surgical aortic valve replacement.
Valve-in-mitral annular calcification and valve-in-ring TMVR were found to be successful.
Patients with symptomatic severe aortic stenosis who had aortic valve replacement deferred vs expedited at the beginning of the COVID-19 pandemic were more likely to be hospitalized for valve-related symptoms or worsening heart failure.
A novel pigtail/J-wire technique for crossing stenotic aortic valves was found to be rapid, simple, and safe to implement.
For patients with symptomatic severe aortic stenosis, deferred aortic valve replacement (AVR) is associated with an increased risk for hospitalization for valve-related symptoms or worsening heart failure.